Tonix Pharmaceuticals Shares 66% Higher After Patent for TNX-801
marketwatch.com
news
2022-06-01 16:28:00

By Chris Wack Tonix Pharmaceuticals Holding Corp. shares jumped 66% to $4.04 after the U.S. Patent and Trademark Office issued a patent for TNX-801 smallpox and monkeypox vaccine and recombinant pox virus platform technology. The patent, entitled "Synthetic Chimeric Poxviruses," includes claims covering synthetic horsepox virus, the basis for the TNX-801 vaccine against other pathogens, including SARS-CoV-2, Tonix said. The patent is expected to provide Tonix with U.S. market exclusivity until 2037, excluding any possible patent-term extensions or patent-term adjustments.
